Madrigal Pharmaceuticals (MDGL) Short Interest Ratio & Short Volume $308.44 +15.03 (+5.12%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Madrigal Pharmaceuticals Short Interest DataMadrigal Pharmaceuticals (MDGL) has a short interest of 4.28 million shares. This marks a -3.39% decrease in short interest from the previous month. The short interest ratio (days to cover) is 10.6, indicating that it would take 10.6 days of the average trading volume of 436,534 shares to cover all short positions.Current Short Interest4,280,000 sharesPrevious Short Interest4,430,000 sharesChange Vs. Previous Month-3.39%Dollar Volume Sold Short$1.40 billionShort Interest Ratio10.6 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares21,810,000 sharesPercentage of Shares Shorted19.62%Today's Trading Volume716,661 sharesAverage Trading Volume436,534 sharesToday's Volume Vs. Average164% Short Selling Madrigal Pharmaceuticals? Sign up to receive the latest short interest report for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartMDGL Short Interest Over TimeMDGL Days to Cover Over TimeMDGL Percentage of Float Shorted Over Time Ad Weiss RatingsBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.This could be his favorite coin. Madrigal Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/20244,280,000 shares $1.40 billion -3.4%N/A10.6 $328.19 11/15/20244,430,000 shares $1.28 billion -2.2%N/A11.3 $288.58 10/31/20244,530,000 shares $1.17 billion +11.9%N/A13.1 $259.34 10/15/20244,050,000 shares $875.49 million +4.9%N/A15.1 $216.17 9/30/20243,860,000 shares $819.17 million +3.5%N/A13.8 $212.22 9/15/20243,730,000 shares $901.91 million -0.8%N/A13.5 $241.80 Get the Latest News and Ratings for MDGL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/31/20243,760,000 shares $929.21 million +0.3%N/A11.5 $247.13 8/15/20243,750,000 shares $916.88 million +1.9%N/A9.5 $244.50 7/31/20243,680,000 shares $1.05 billion -10.5%N/A8.6 $284.66 7/15/20244,110,000 shares $1.15 billion +0.7%N/A9.1 $279.95 6/30/20244,080,000 shares $1.14 billion -7.9%N/A9.1 $280.16 6/15/20244,430,000 shares $1.23 billion -15.3%N/A9.5 $277.59 5/31/20245,230,000 shares $1.24 billion +25.4%N/A9.4 $236.16 5/15/20244,170,000 shares $882.91 million +4.8%N/A8.1 $211.73 4/30/20243,980,000 shares $812.00 million +16.7%N/A6.9 $204.02 4/15/20243,410,000 shares $788.97 million +1.5%N/A5.9 $231.37 3/31/20243,360,000 shares $897.25 million +3.1%N/A6 $267.04 3/15/20243,260,000 shares $881.41 million -5.8%20.2%5.9 $270.37 2/29/20243,460,000 shares $817.25 million +2.1%21.4%7.3 $236.20 2/15/20243,390,000 shares $753.33 million +8.0%21.1%7.6 $222.22 1/31/20243,140,000 shares $680.47 million -5.1%19.5%7.2 $216.71 1/15/20243,310,000 shares $780.50 million +1.9%21.1%8.6 $235.80 12/31/20233,250,000 shares $751.99 million +5.9%20.7%7.9 $231.38 12/15/20233,070,000 shares $727.99 million -11.5%19.5%6.7 $237.13 11/30/20233,470,000 shares $705.45 million +0.3%24.4%7.1 $203.30 11/15/20233,460,000 shares $559.41 million +1.5%24.3%7.7 $161.68 10/31/20233,410,000 shares $448.01 million +13.3%24.7%8.2 $131.38 10/15/20233,010,000 shares $422.51 million +13.6%21.8%7.6 $140.37 9/30/20232,650,000 shares $387.01 million +24.4%19.2%7.4 $146.04 9/15/20232,130,000 shares $374.65 million +8.7%16.5%6.3 $175.89 8/31/20231,960,000 shares $352.80 million +8.3%15.2%6.3 $180.00 8/15/20231,810,000 shares $315.25 million -1.1%14.0%5.7 $174.17 7/31/20231,830,000 shares $375.70 million -3.2%13.8%5.3 $205.30 7/15/20231,890,000 shares $426.71 million +7.4%14.3%5.4 $225.77 6/30/20231,760,000 shares $406.56 million +10.0%13.3%4.7 $231.00 6/15/20231,600,000 shares $408.85 million +10.3%12.1%4.7 $255.53 5/31/20231,450,000 shares $403.69 million +15.1%10.4%3.9 $278.41 5/15/20231,260,000 shares $365.77 million -8.7%9.0%3.1 $290.29 4/30/20231,380,000 shares $430.56 million -6.8%10.0%3.3 $312.00 4/15/20231,480,000 shares $354.89 million +19.4%10.8%3.7 $239.79Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. 3/31/20231,240,000 shares $300.40 million +3.3%9.2%3.1 $242.26 3/15/20231,200,000 shares $286.57 million +16.5%8.7%2.3 $238.81 2/28/20231,030,000 shares $279.14 million +9.2%7.4%1.6 $271.01 2/15/2023942,900 shares $266.14 million 0.0%7.2%1.5 $282.26 1/31/2023943,300 shares $271.91 million -3.3%7.2%1.6 $288.25 1/15/2023975,300 shares $292.57 million -12.9%7.5%1.6 $299.98 12/30/20221,120,000 shares $325.08 million -52.7%9.0%1.9 $290.25 12/15/20222,370,000 shares $149.07 million +9.7%19.1%4.3 $62.90 11/30/20222,160,000 shares $151.44 million +3.9%17.4%7.3 $70.11 11/15/20222,080,000 shares $146.68 million +14.3%16.8%7.9 $70.52 10/31/20221,820,000 shares $128.89 million +17.4%14.7%7.4 $70.82 10/15/20221,550,000 shares $100.27 million +1.3%12.5%6.6 $64.69 9/30/20221,530,000 shares $99.43 million +2.7%12.4%7.2 $64.99 9/15/20221,490,000 shares $103.70 million +1.4%12.1%7.4 $69.60 8/31/20221,470,000 shares $106.02 million -4.6%11.9%7.8 $72.12 8/15/20221,540,000 shares $118.13 million -3.8%12.5%8.6 $76.71 7/31/20221,600,000 shares $100.51 million +3.2%12.9%8.4 $62.82 7/15/20221,550,000 shares $107.24 million -4.3%12.5%8.1 $69.19 6/30/20221,620,000 shares $115.96 million -2.4%13.1%8.1 $71.58 6/15/20221,660,000 shares $112.71 million +3.8%13.4%8.6 $67.90 5/31/20221,600,000 shares $106.22 million -5.3%12.9%8.5 $66.39 5/15/20221,690,000 shares $111.08 million -2.9%13.6%8.8 $65.73 4/30/20221,740,000 shares $121.80 million +1.8%14.0%8.2 $70.00 4/15/20221,710,000 shares $135.89 million -5.5%13.8%7.3 $79.47 3/31/20221,810,000 shares $177.60 million -9.1%14.6%7.8 $98.12 3/15/20221,990,000 shares $179.10 million +0.5%16.0%8.5 $90.00 2/28/20221,980,000 shares $183.84 million -1.5%16.0%8.1 $92.85 2/15/20222,010,000 shares $180.72 million +12.3%16.2%8.4 $89.91 1/31/20221,790,000 shares $103.07 million +19.3%14.4%8.5 $57.58 1/15/20221,500,000 shares $117.68 million +8.7%12.1%9.4 $78.45 12/31/20211,380,000 shares $116.94 million -6.8%11.1%9.6 $84.74 12/15/20211,480,000 shares $110.82 million +7.3%11.9%10.8 $74.88 11/30/20211,380,000 shares $114.14 million +2.2%12.0%12 $82.71 11/15/20211,350,000 shares $122.00 million -3.6%11.8%12.7 $90.37 10/29/20211,400,000 shares $108.85 million +3.7%12.2%13.3 $77.75 10/15/20211,350,000 shares $116.33 million -6.9%12.1%13.5 $86.17 9/30/20211,450,000 shares $115.70 million No Change13.0%14.1 $79.79 9/15/20211,450,000 shares $115.10 million -7.1%13.0%11.9 $79.38 8/31/20211,560,000 shares $129.09 million -5.5%14.0%12.2 $82.75 8/13/20211,650,000 shares $140.02 million +3.1%14.8%10.9 $84.86 7/30/20211,600,000 shares $139.71 million -4.2%14.4%10.4 $87.32 7/15/20211,670,000 shares $157.95 million No Change15.0%11 $94.58 6/30/20211,670,000 shares $162.67 million -5.1%15.0%10.9 $97.41 6/15/20211,760,000 shares $185.66 million -7.9%15.8%12.4 $105.49 5/28/20211,910,000 shares $214.49 million -7.3%17.2%14.1 $112.30 5/14/20212,060,000 shares $271.12 million +1.0%18.9%16.5 $131.61 4/30/20212,040,000 shares $280.68 million -8.5%18.7%14.8 $137.59 4/15/20212,230,000 shares $269.70 million -5.1%21.8%12.3 $120.94 3/31/20212,350,000 shares $273.80 million -4.5%23.4%12.7 $116.51 3/15/20212,460,000 shares $289.89 million -7.5%24.5%12.4 $117.84Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. 2/26/20212,660,000 shares $327.34 million -4.0%26.5%13.5 $123.06 2/12/20212,770,000 shares $334.67 million +5.3%28.6%14.4 $120.82 1/29/20212,630,000 shares $304.11 million -8.4%26.0%13.7 $115.63 1/15/20212,870,000 shares $327.18 million +4.7%28.4%17.9 $114.00 12/31/20202,740,000 shares $304.47 million +12.3%27.1%19.3 $111.12 12/15/20202,440,000 shares $294.58 million -2.4%24.2%17.2 $120.73 11/30/20202,500,000 shares $297.78 million +5.5%24.8%16.9 $119.11 11/15/20202,370,000 shares $303.57 million -4.4%23.5%16.3 $128.09 10/30/20202,480,000 shares $318.23 million +0.8%24.6%18.5 $128.32 10/15/20202,460,000 shares $312.94 million No Change24.4%19.1 $127.21 9/30/20202,460,000 shares $292.08 million -13.7%24.4%19.4 $118.73 9/15/20202,850,000 shares $304.72 million +2.5%28.3%21.4 $106.92 8/31/20202,780,000 shares $299.41 million -1.8%27.6%25 $107.70 8/14/20202,830,000 shares $301.37 million +0.4%32.6%24.3 $106.49 7/31/20202,820,000 shares $289.36 million +0.7%32.6%18.9 $102.61 7/15/20202,800,000 shares $291.00 million -4.8%32.4%16.4 $103.93 6/30/20202,940,000 shares $302.06 million +1.0%34.1%14.9 $102.74 6/15/20202,910,000 shares $314.43 million +1.8%33.7%13.9 $108.05 5/29/20202,860,000 shares $332.96 million -8.6%33.1%12.5 $116.42 5/15/20203,130,000 shares $370.59 million -7.7%37.2%13.3 $118.40 4/30/20203,390,000 shares $283.68 million No Change40.3%16.4 $83.68 4/15/20203,390,000 shares $250.11 million +16.5%34.3%16.8 $73.78 3/31/20202,910,000 shares $263.21 million +18.8%29.5%15.6 $90.45 3/13/20202,450,200 shares $164.63 million -3.5%24.8%14.5 $67.19 2/28/20202,540,000 shares $176.40 million -1.9%25.7%13.2 $69.45 2/14/20202,590,000 shares $222.25 million +0.8%26.2%13.9 $85.81 1/31/20202,570,000 shares $217.22 million +6.6%26.0%13.5 $84.52 1/15/20202,410,000 shares $218.25 million +1.7%24.4%12.9 $90.56 12/31/20192,370,000 shares $182.44 million -1.3%24.0%13.7 $76.98 MDGL Short Interest - Frequently Asked Questions What is Madrigal Pharmaceuticals' current short interest? Short interest is the volume of Madrigal Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of November 30th, traders have sold 4,280,000 shares of MDGL short. Learn More on Madrigal Pharmaceuticals' current short interest. What is a good short interest ratio for Madrigal Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MDGL shares currently have a short interest ratio of 11.0. Learn More on Madrigal Pharmaceuticals's short interest ratio. Which institutional investors are shorting Madrigal Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Madrigal Pharmaceuticals: Jane Street Group LLC, Wolverine Trading LLC, Ikarian Capital LLC, Walleye Capital LLC, and Citigroup Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Madrigal Pharmaceuticals' short interest increasing or decreasing? Madrigal Pharmaceuticals saw a drop in short interest during the month of November. As of November 30th, there was short interest totaling 4,280,000 shares, a drop of 3.4% from the previous total of 4,430,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Madrigal Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "biotechnology" compare to Madrigal Pharmaceuticals: Biogen Inc. (1.88%), United Therapeutics Co. (4.75%), Neurocrine Biosciences, Inc. (3.86%), Incyte Co. (3.16%), BioMarin Pharmaceutical Inc. (3.02%), Exact Sciences Co. (6.39%), Exelixis, Inc. (3.00%), Repligen Co. (6.34%), Halozyme Therapeutics, Inc. (6.81%), Ionis Pharmaceuticals, Inc. (7.18%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Madrigal Pharmaceuticals stock? Short selling MDGL is an investing strategy that aims to generate trading profit from Madrigal Pharmaceuticals as its price is falling. MDGL shares are trading up $15.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Madrigal Pharmaceuticals? A short squeeze for Madrigal Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MDGL, which in turn drives the price of the stock up even further. How often is Madrigal Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MDGL, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies BIIB Short Interest UTHR Short Interest NBIX Short Interest INCY Short Interest BMRN Short Interest EXAS Short Interest EXEL Short Interest RGEN Short Interest HALO Short Interest IONS Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MDGL) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
